Induction docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patients with locally advanced squamous cell carcinoma of the head and neck. A randomized phase III factorial study.

Trial Profile

Induction docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patients with locally advanced squamous cell carcinoma of the head and neck. A randomized phase III factorial study.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 Results published in the Annals of Oncology
    • 04 Jun 2013 Efficacy results for the chemoradiotherapy versus cetuximab + radiotherapy comparison presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 30 Sep 2012 Interim tolerability analysis in 348 patients presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top